Payment overview · 2025
General Payments
$227.21
2 reported records · 2 companies
Healthcare provider profile · identity verified
Oliver B Diaz, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BRISTOL, CT · NPI 1124037312
Verified facts
What the public records show
CMS Open Payments records show Oliver B Diaz, M.D. received $227.21 in general payments during 2025 across 2 reported records.
Lilly USA, LLC accounted for 54.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $123.06 | 54.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $104.15 | 45.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $227.21 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $227.21 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 146 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
146 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
146 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 431 | 106 |
| Levothyroxine Sodium | Levothyroxine Sodium | 392 | 96 |
| Metoprolol Succinate | Metoprolol Succinate | 322 | 76 |
| Atorvastatin Calcium | Atorvastatin Calcium | 286 | 69 |
| Metformin Hcl | Metformin Hcl | 258 | 66 |
| Gabapentin | Gabapentin | 251 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 251 | 77 |
| Alprazolam | Alprazolam | 247 | 43 |
| Omeprazole | Omeprazole | 239 | 50 |
| Xarelto | Rivaroxaban | 200 | 40 |
| Lisinopril | Lisinopril | 198 | 43 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 176 | 49 |
| Furosemide | Furosemide | 174 | 42 |
| Spironolactone | Spironolactone | 152 | 36 |
| Tramadol Hcl | Tramadol Hcl | 147 | 25 |
| Jardiance | Empagliflozin | 146 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 145 | 33 |
| Januvia | Sitagliptin Phosphate | 145 | 26 |
| Montelukast Sodium | Montelukast Sodium | 143 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 141 | 16 |
| Baclofen | Baclofen | 137 | 30 |
| Trazodone Hcl | Trazodone Hcl | 137 | 27 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 134 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 132 | 31 |
| Glipizide | Glipizide | 131 | 27 |
| Lovastatin | Lovastatin | 130 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 126 | 29 |
| Eliquis | Apixaban | 125 | 29 |
| Torsemide | Torsemide | 122 | 35 |
| Digoxin | Digoxin | 119 | 29 |
| Losartan Potassium | Losartan Potassium | 117 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 114 | 35 |
| Carvedilol | Carvedilol | 112 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 111 | 17 |
| Farxiga | Dapagliflozin Propanediol | 106 | 25 |
| Oxycodone Hcl | Oxycodone Hcl | 102 | suppressed |
| Allopurinol | Allopurinol | 101 | 26 |
| Potassium Chloride | Potassium Chloride | 101 | 27 |
| Lorazepam | Lorazepam | 91 | 23 |
| Labetalol Hcl | Labetalol Hcl | 90 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 90 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 78 | 17 |
| Meclizine Hcl | Meclizine Hcl | 77 | 21 |
| Prednisone | Prednisone | 75 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 71 | 13 |
| Meloxicam | Meloxicam | 66 | 18 |
| Alendronate Sodium | Alendronate Sodium | 65 | 16 |
| Memantine Hcl | Memantine Hcl | 65 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 65 | 13 |
| Warfarin Sodium | Warfarin Sodium | 61 | suppressed |
| Ezetimibe | Ezetimibe | 59 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 59 | suppressed |
| Synthroid | Levothyroxine Sodium | 57 | 12 |
| Irbesartan | Irbesartan | 56 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 55 | 17 |
| Simvastatin | Simvastatin | 55 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 53 | 17 |
| Entresto | Sacubitril/Valsartan | 53 | suppressed |
| Pregabalin | Pregabalin | 53 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 51 | suppressed |
| Glipizide Er | Glipizide | 50 | 14 |
| Indapamide | Indapamide | 50 | 14 |
| Solifenacin Succinate | Solifenacin Succinate | 47 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 45 | suppressed |
| Cephalexin | Cephalexin | 44 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 44 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 43 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 37 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Celecoxib | Celecoxib | 33 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Azithromycin | Azithromycin | 31 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 31 | suppressed |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | suppressed |
| Diazepam | Diazepam | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 28 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | 13 |
| Desoximetasone | Desoximetasone | 27 | 12 |
| Linzess | Linaclotide | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 26 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 22 |
| Temazepam | Temazepam | 25 | suppressed |
| Clonazepam | Clonazepam | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 21 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 21 | suppressed |
| Vraylar | Cariprazine Hcl | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 20 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 19 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 19 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 16 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Sunosi | Solriamfetol Hcl | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Dexamethasone | Dexamethasone | 11 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 11 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 11 | suppressed |
| Seglentis | Tramadol Hcl/Celecoxib | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $227.21 · 2 records | Lilly USA, LLC | JARDIANCE | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error